Pre-clinical activity of tipifarnib in CTCL

Pre-clinical activity of tipifarnib in CTCL

VJHemOnc

1 year
158 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Providing us with insight into a trial not yet published, Pierluigi Porcu, MD, from Jefferson Hospital, Sidney Kimmel Cancer Center, Philadelphia, PN, discusses his teams investigation into potential molecular biomarkers of response in mice induced to overexpress cytokine IL-15. Dr Porcu uses tipifarnib, a farnesyltransferase inhibitor which targets the RAS pathway, to treat the induced cutaneous T-cell lymphoma developed in the mice. Currently, he is focusing on looking for biomarkers of response from these animal trials. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX
Up Next Autoplay
Observations from PROVe Study #EORTC2019
Observations from PROVe Study #EORTC2019
Category: Non-Hodgkin Lymphoma
27 Views
Cancer-News 1 month
PROVe Study: How Long Are Patients On Therapy? #EORTC2019
PROVe Study: How Long Are Patients On Therapy? #EORTC2019
Category: Non-Hodgkin Lymphoma
14 Views
Cancer-News 1 month
PROVe study: Treatment of MF-CTCL Patients #EORTC2019
PROVe study: Treatment of MF-CTCL Patients #EORTC2019
Category: Non-Hodgkin Lymphoma
18 Views
Cancer-News 1 month
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
Category: Non-Hodgkin Lymphoma
14 Views
Cancer-News 1 month
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
Category: Non-Hodgkin Lymphoma
231 Views
cancergrace 4 months
CLL and Non-Hodgkin Lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
CLL and Non-Hodgkin Lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
Category: Non-Hodgkin Lymphoma
123 Views
cancergrace 4 months
Chronic Lymphocytic Leukemia,  Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Category: Non-Hodgkin Lymphoma
115 Views
cancergrace 4 months
The Clinical Study Investigating Mosunetuzumab
The Clinical Study Investigating Mosunetuzumab
Category: Non-Hodgkin Lymphoma
111 Views
obr 10 months
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Category: Non-Hodgkin Lymphoma
47 Views
obr 10 months
Non-hodgkin lymphoma advances in 2018
Non-hodgkin lymphoma advances in 2018
Category: Non-Hodgkin Lymphoma
178 Views
VJHemOnc 1 year